Hyperway Pharmaceutical Co. Ltd. and Shenzhen Hyperway Pharmaceuticals Co. Ltd. have disclosed new GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
Work at Hyperway Pharmaceutical Co. Ltd. has led to the discovery of a novel PAK4 inhibitor, HBW-008-A, the efficacy of which has been assessed in preclinical cancer models.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results